9 research firms give NuVasive a ‘buy’ rating — 3 quick notes

Nine of 13 research firms currently covering San Diego-based NuVasive believe the medical device company will continue trending upwards, according to Sports Perspective.

Advertisement

Here are three things to know:

 

1. One analyst rated the stock with a sell rating while three gave a hold rating.

 

2. The average one year price target issued by brokers who reported on the stock is $68.60.

 

3. NuVasive is a medical device company focused on creating minimally invasive spine products.

 

More device articles:

Medovex, AlfaMed, & more: 4 recent device company partnerships

Reprocessed medical devices market gaining traction — 4 observations

4 things to know about Intelligent Implant Systems

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.